Trends in the European HIV/AIDS epidemic: a perspective from Italy

被引：0
作者：
Madeddu, Giordano [1 ]
Rezza, Giovanni [2 ]
Mura, Maria Stella
机构：
[1] Univ Sassari, Ist Malattie Infett, Dept Infect Dis, I-07100 Sassari, Italy
[2] Ist Super Sanita, Dept Infect Dis, Epidemiol Unit, I-00166 Rome, Italy
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2009年 / 7卷 / 01期
关键词：
drug resistance; epidemiologic trend; HAART; HIV; HIV subtype; population effect; sexual transmission; HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; EXPERIENCED HIV-1-INFECTED PATIENTS; OPTIMIZED BACKGROUND REGIMEN; ANTIVIRAL NUCLEOSIDE ANALOGS; SEXUAL RISK BEHAVIOR; DRUG-RESISTANT HIV-1; PROTEASE INHIBITORS; VIRAL LOAD;
D O I：
10.1586/14787210.7.1.25
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The HIV/AIDS epidemic represents one of the major public-health challenges in present days. Despite the relevant improvement in the prognosis of HIV disease following the introduction of highly active antiretroviral therapy (HAART), numerous new challenges are progressively emerging as patient characteristics evolve. In this article, we give an insight into more actual topics in the HIV/AIDS epidemic in Italy and Europe, including recent epidemiological trends, emerging drug resistance and non-B-subtype circulation, the lights and shadows of HAART and the potential of HARRT to reduce sexual transmission of HIV.
引用
收藏
页码：25 / 36
页数：12
相关论文
共 116 条
  • [1] [Anonymous], J INFECT DIS
  • [2] [Anonymous], 2008, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Management
  • [3] Anostos K, 2007, ANTIVIR THER, V12, P1049
  • [4] Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis
    Arribas, Jose R.
    Pozniak, Anton L.
    Gallant, Joel E.
    DeJesus, Edwin
    Gazzard, Brian
    Campo, Rafael E.
    Chen, Shan-Shan
    McColl, Damian
    Holmes, Charles B.
    Enejosa, Jeffrey
    Toole, John J.
    Cheng, Andrew K.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) : 74 - 78
  • [5] Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression
    Bangsberg, David R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) : 939 - 941
  • [6] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    Bangsberg, DR
    Hecht, FM
    Charlebois, ED
    Zolopa, AR
    Holodniy, M
    Sheiner, L
    Bamberger, JD
    Chesney, MA
    Moss, A
    [J]. AIDS, 2000, 14 (04) : 357 - 366
  • [7] Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors
    Birkus, G
    Hitchcock, MJM
    Cihlar, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 716 - 723
  • [8] BRANSON BM, 2006, MMWR-MORBID MORTAL W, V50, P1
  • [9] A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
    Brenner, B
    Turner, D
    Oliveira, M
    Moisi, D
    Detorio, M
    Carobene, M
    Marlink, RG
    Schapiro, J
    Roger, M
    Wainberg, MA
    [J]. AIDS, 2003, 17 (01) : F1 - F5
  • [10] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
12345678910